Close Menu

Sirna to Manufacture Archemix Drug Candidate

Sirna Therapeutics has signed on to manufacture for Archemix the antithrombin aptamer ARC183, the companies said this week.

ARC183 is Archemix’s first drug development candidate and is being tested for use as an anti- coagulant/anti-thrombotic in coronary artery bypass graft surgery. Under the arrangement, Sirna will make and supply Archemix with the agent for use in its development efforts through phase IIa clinical trials.

Specific terms of the deal were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.

Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.

Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.

In Science this week: three studies from the Ruminant Genome Project, and more.